X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-05-18 | MLYS | Mineralys Therapeutics, Inc. | Rodman David Malcom | Chief Medical Officer | S - Sale+OE | $27.55 | -417 | 63,443 | -1% | -$11,488 | |||||
| D | 2026-05-15 | PHVS | Pharvaris N.V. | Glassman Robert | Dir | S - Sale+OE | $29.82 | -10,000 | 10,500 | -49% | -$298,245 | |||||
2026-05-15 | PHVS | Pharvaris N.V. | Abele Stefan Andreas | Chief Technical Ops Officer | S - Sale | $29.82 | -8,748 | 35,194 | -20% | -$260,864 | ||||||
2026-05-15 | PHVS | Pharvaris N.V. | Souverijns Wim | Chief Commercial Officer | S - Sale | $29.92 | -10,000 | 45,111 | -18% | -$299,163 | ||||||
2026-05-15 | PCSA | Processa Pharmaceuticals, Inc. | Ng George K | CEO | P - Purchase | $2.97 | +1,843 | 12,129 | +18% | +$5,474 | ||||||
2026-05-15 | PCSA | Processa Pharmaceuticals, Inc. | Young David | Pres Research, Development | P - Purchase | $2.97 | +1,545 | 17,761 | +10% | +$4,589 | ||||||
2026-05-15 | PCSA | Processa Pharmaceuticals, Inc. | Lin Patrick | Chief Business - Strategy Off | P - Purchase | $2.97 | +1,369 | 9,334 | +17% | +$4,066 | ||||||
2026-05-15 | PCSA | Processa Pharmaceuticals, Inc. | Guy Wendy | Chief Administrative Officer | P - Purchase | $2.97 | +1,583 | 8,344 | +23% | +$4,702 | ||||||
2026-05-15 | PCSA | Processa Pharmaceuticals, Inc. | Skibsted Russell | CFO | P - Purchase | $2.97 | +1,984 | 8,466 | +31% | +$5,892 | ||||||
| A | 2026-04-15 | PCSA | Processa Pharmaceuticals, Inc. | Ng George K | CEO | P - Purchase | $2.97 | +1,843 | 8,267 | +29% | +$5,474 | |||||
| D | 2026-05-15 | PTCT | Ptc Therapeutics, Inc. | Boulding Mark Elliott | EVP, CLO | S - Sale+OE | $72.18 | -2,812 | 105,212 | -3% | -$202,958 | |||||
| A | 2026-04-30 | PCSA | Processa Pharmaceuticals, Inc. | Bigora Sian | Chief Development Officer | P - Purchase | $2.71 | +1,971 | 7,748 | +34% | +$5,341 | |||||
| D | 2026-05-15 | ELAN | Elanco Animal Health Inc | Modi Rajeev A. | SEE REMARKS | P - Purchase | $20.35 | +4,911 | 160,812 | +3% | +$99,939 | |||||
| D | 2026-05-15 | ELAN | Elanco Animal Health Inc | Simmons Jeffrey N | Pres, CEO, Dir | P - Purchase | $20.09 | +4,971 | 2,223,869 | 0% | +$99,843 | |||||
| D | 2026-05-18 | UTHR | United Therapeutics Corp | Edgemond James | CFO, TREASURER | S - Sale+OE | $567.31 | -10,000 | 18,876 | -35% | -$5,673,098 | |||||
2026-05-18 | BBIO | Bridgebio Pharma, Inc. | Trimarchi Thomas | Pres, CFO | S - Sale | $65.08 | -13,651 | 359,194 | -4% | -$888,419 | ||||||
| D | 2026-05-15 | BBIO | Bridgebio Pharma, Inc. | Scott Randal W. | Dir | S - Sale+OE | $67.15 | -10,000 | 15,589 | -39% | -$671,456 | |||||
| DM | 2026-05-15 | ZLAB | Zai Lab Ltd | Du Ying | Chairperson, CEO | S - Sale+OE | $19.87 | -100,000 | 1,122,626 | -8% | -$1,986,875 | |||||
| D | 2026-05-15 | RYTM | Rhythm Pharmaceuticals, Inc. | German Christopher Paul | Corporate Controller, CAO | S - Sale+OE | $92.21 | -4,643 | 0 | -100% | -$428,131 | |||||
2026-05-15 | KROS | Keros Therapeutics, Inc. | Bienaime Jean Jacques | Dir | P - Purchase | $10.58 | +1,000 | 9,450 | +12% | +$10,580 | ||||||
| D | 2026-05-15 | AVTX | Avalo Therapeutics, Inc. | Doyle Mittie | Chief Medical Officer | S - Sale+OE | $18.76 | -3,000 | 3,622 | -45% | -$56,280 | |||||
| D | 2026-05-18 | KALV | Kalvista Pharmaceuticals, Inc. | Yea Christopher | CHIEF DEVELOPMENT OFFICER | S - Sale+OE | $26.76 | -1,108 | 227,367 | 0% | -$29,650 | |||||
2026-05-15 | TVTX | Travere Therapeutics, Inc. | Coughlin Timothy | Dir | S - Sale | $43.49 | -3,250 | 52,250 | -6% | -$141,343 | ||||||
| D | 2026-05-18 | MCRB | Seres Therapeutics, Inc. | Desrosier Thomas | See Remarks | S - Sale+OE | $7.53 | -79 | 7,954 | -1% | -$595 | |||||
| D | 2026-05-18 | MCRB | Seres Therapeutics, Inc. | Shaff Eric D. | Dir | S - Sale+OE | $7.53 | -259 | 12,040 | -2% | -$1,950 | |||||
| D | 2026-05-18 | MCRB | Seres Therapeutics, Inc. | Henn Matthew R | See Remarks | S - Sale+OE | $7.53 | -77 | 7,838 | -1% | -$580 | |||||
| D | 2026-05-18 | MCRB | Seres Therapeutics, Inc. | Brady Kelly | See Remarks | S - Sale+OE | $7.53 | -59 | 8,562 | -1% | -$444 | |||||
2026-05-15 | VRTX | Vertex Pharmaceuticals Inc / Ma | Bunnage Mark E. | EVP, Chief Scientific Officer | S - Sale | $453.45 | -33 | 7,284 | 0% | -$14,964 | ||||||
| D | 2026-05-18 | KALV | Kalvista Pharmaceuticals, Inc. | Audhya Paul K. | CHIEF MEDICAL OFFICER | S - Sale+OE | $26.76 | -1,032 | 143,934 | -1% | -$27,616 | |||||
2026-05-15 | VRTX | Vertex Pharmaceuticals Inc / Ma | Bozic Carmen | EVP, CMO | S - Sale | $453.45 | -1,354 | 24,734 | -5% | -$613,971 | ||||||
| D | 2026-05-18 | KALV | Kalvista Pharmaceuticals, Inc. | Palleiko Benjamin L | CEO | S - Sale+OE | $26.76 | -1,129 | 467,665 | 0% | -$30,212 | |||||
| D | 2026-05-15 | ARDX | Ardelyx, Inc. | Raab Michael | Pres, CEO | S - Sale+OE | $6.28 | -41,666 | 1,800,145 | -2% | -$261,612 | |||||
| A | 2026-05-14 | KYNB | Kyntra Bio, Inc. | Wettig Thane | CEO | P - Purchase | $7.09 | +2,800 | 27,243 | +11% | +$19,852 | |||||
2026-05-15 | IMNM | Immunome Inc. | Bienaime Jean Jacques | Dir | P - Purchase | $20.70 | +5,000 | 43,415 | +13% | +$103,500 | ||||||
2026-05-18 | HROW | Harrow, Inc. | Graves Adrienne L | Dir | P - Purchase | $31.07 | +1,000 | 1,000 | New | +$31,070 | ||||||
2026-05-18 | HROW | Harrow, Inc. | Silvernail Lauren P | Dir | P - Purchase | $31.00 | +1,000 | 1,000 | New | +$31,000 | ||||||
2026-05-18 | MPLT | Maplight Therapeutics, Inc. | Kroeger Christopher A. | CEO | S - Sale | $27.19 | -118,235 | 1,394,094 | -8% | -$3,215,000 | ||||||
2026-05-18 | ZBIO | Zenas Biopharma, Inc. | Moulder Leon O Jr | CEO | P - Purchase | $16.88 | +60,000 | 2,306,122 | +3% | +$1,012,800 | ||||||
| D | 2026-05-15 | MIRM | Mirum Pharmaceuticals, Inc. | Ramasastry Saira | Dir | S - Sale+OE | $109.47 | -2,000 | 0 | -100% | -$218,940 | |||||
| D | 2026-05-18 | RARE | Ultragenyx Pharmaceutical Inc. | Suliman Shehnaaz | Dir | S - Sale+OE | $25.12 | -5,740 | 27,951 | -17% | -$144,189 | |||||
| D | 2026-05-15 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $568.11 | -9,500 | 679,797 | -1% | -$5,397,077 | |||||
| D | 2026-05-18 | ORKA | Oruka Therapeutics, Inc. | Agarwal Arjun | SVP, Finance | S - Sale+OE | $59.07 | -10,290 | 16,406 | -39% | -$607,806 | |||||
2026-05-18 | MDGL | Madrigal Pharmaceuticals, Inc. | Soergel David | Chief Medical Officer | S - Sale | $515.90 | -844 | 11,075 | -7% | -$435,420 | ||||||
2026-05-15 | ACIU | Ac Immune Sa | Pfeifer Andrea | CEO | S - Sale | $2.79 | -10,000 | 3,834,288 | 0% | -$27,935 | ||||||
| D | 2026-05-15 | BCAX | Bicara Therapeutics Inc. | Cohlhepp Ryan | Pres, COO | S - Sale+OE | $20.29 | -12,500 | 191,641 | -6% | -$253,649 | |||||
| D | 2026-05-15 | COLL | Collegium Pharmaceutical, Inc | Freund John Gordon | Dir | S - Sale+OE | $34.54 | -4,127 | 115,726 | -3% | -$142,547 | |||||
2026-05-14 | NBP | Novabridge Biosciences | Cao Sean Wuxiong | See Remarks | S - Sale | $1.99 | -21,399 | 35,073 | -38% | -$42,584 | ||||||
| D | 2026-05-14 | TEVA | Teva Pharmaceutical Industries Ltd | Lippman Evan | EVP, Business Development | S - Sale+OE | $35.58 | -41,658 | 44,191 | -49% | -$1,482,367 | |||||
| DM | 2026-05-14 | GYRE | Gyre Therapeutics, Inc. | Ye Weiguo | COO | S - Sale+OE | $6.79 | -28,680 | 700,000 | -4% | -$194,773 | |||||
2026-05-14 | TEVA | Teva Pharmaceutical Industries Ltd | Kalif Eliyahu Sharon | EVP, CFO | S - Sale | $35.61 | -153,251 | 172,184 | -47% | -$5,457,375 | ||||||
2026-05-15 | AQST | Aquestive Therapeutics, Inc. | Barber Daniel | Pres, CEO | S - Sale | $4.29 | -8,257 | 660,574 | -1% | -$35,413 | ||||||
2026-05-14 | ABCL | Abcellera Biologics Inc. | Montalbano John S. | Dir | P - Purchase | $4.77 | +20,000 | 246,000 | +9% | +$95,400 | ||||||
2026-05-14 | KYNB | Kyntra Bio, Inc. | Wettig Thane | CEO | P - Purchase | $7.09 | +2,800 | 27,243 | +11% | +$19,852 | ||||||
| M | 2026-05-13 | RLYB | Rallybio Corp | Adar1 Capital Management, LLC | 10% | P - Purchase | $13.99 | +79,559 | 910,143 | +10% | +$1,112,977 | |||||
| D | 2026-05-15 | ORKA | Oruka Therapeutics, Inc. | Goncalves Joana | Chief Medical Officer | S - Sale+OE | $61.85 | -7,000 | 33,377 | -17% | -$432,935 | |||||
| M | 2026-05-13 | LQDA | Liquidia Corp | Jeffs Roger | CEO | S - Sale | $57.32 | -75,000 | 2,382,198 | -3% | -$4,298,765 | |||||
| DM | 2026-05-13 | IONS | Ionis Pharmaceuticals Inc | Monia Brett P | CEO | S - Sale+OE | $78.49 | -4,536 | 242,662 | -2% | -$356,012 | |||||
2026-05-14 | PTCT | Ptc Therapeutics, Inc. | Klein Matthew B. | CEO | S - Sale | $72.95 | -12,572 | 393,998 | -3% | -$917,154 | ||||||
| D | 2026-05-14 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $574.48 | -9,500 | 679,797 | -1% | -$5,457,566 | |||||
| D | 2026-05-14 | UTHR | United Therapeutics Corp | Edgemond James | CFO, TREASURER | S - Sale+OE | $574.48 | -10,000 | 18,876 | -35% | -$5,744,746 | |||||
2026-05-15 | ABEO | Abeona Therapeutics Inc. | Crombez Eric | Dir | S - Sale | $5.53 | -26,143 | 37,313 | -41% | -$144,636 | ||||||
2026-05-14 | ZLAB | Zai Lab Ltd | Edmondson Frazor Titus III | GC | S - Sale | $20.19 | -3,517 | 19,849 | -15% | -$71,008 | ||||||
| DM | 2026-05-13 | ZLAB | Zai Lab Ltd | Du Ying | Chairperson, CEO | S - Sale+OE | $20.03 | -100,000 | 1,122,626 | -8% | -$2,003,044 | |||||
| D | 2026-05-13 | ONC | Beone Medicines Ltd. | Lee Chan Henry | SVP, GC | S - Sale+OE | $310.72 | -332 | 318,370 | 0% | -$103,159 | |||||
2026-05-14 | RPRX | Royalty Pharma Plc | Urist Marshall | EVP, Research, Investments | S - Sale | $53.06 | -13,684 | 50,901 | -21% | -$726,137 | ||||||
2026-05-14 | RPRX | Royalty Pharma Plc | Norden Gregory | Dir | S - Sale | $53.00 | -3,045 | 191,803 | -2% | -$161,385 | ||||||
| M | 2026-04-02 | SNSE | Sensei Biotherapeutics, Inc. | Millennium Management LLC | 10% | P - Purchase | $33.54 | +4,215 | 133,986 | +3% | +$141,364 | |||||
| M | 2026-04-02 | SNSE | Sensei Biotherapeutics, Inc. | Millennium Management LLC | 10% | S - Sale | $31.51 | -17,076 | 133,986 | -11% | -$538,114 | |||||
| M | 2026-03-31 | SNSE | Sensei Biotherapeutics, Inc. | Millennium Management LLC | 10% | P - Purchase | $31.37 | +12,180 | 147,731 | +9% | +$382,100 | |||||
| M | 2026-03-31 | SNSE | Sensei Biotherapeutics, Inc. | Millennium Management LLC | 10% | S - Sale | $28.07 | -2,741 | 147,731 | -2% | -$76,949 | |||||
| M | 2026-03-26 | SNSE | Sensei Biotherapeutics, Inc. | Millennium Management LLC | 10% | P - Purchase | $26.75 | +30,585 | 145,678 | +27% | +$818,257 | |||||
| M | 2026-03-26 | SNSE | Sensei Biotherapeutics, Inc. | Millennium Management LLC | 10% | S - Sale | $27.50 | -3,250 | 145,678 | -2% | -$89,390 | |||||
2026-05-14 | KPTI | Karyopharm Therapeutics Inc. | Poulton Stuart | EVP, Chief Development Officer | S - Sale | $9.50 | -403 | 94,821 | 0% | -$3,829 | ||||||
2026-05-13 | INSM | Insmed Inc | Bonstein Sara | CFO | S - Sale | $116.18 | -8,272 | 71,486 | -10% | -$961,041 | ||||||
2026-05-13 | INSM | Insmed Inc | Adsett Roger | COO | S - Sale | $116.18 | -5,837 | 100,973 | -5% | -$678,143 | ||||||
| M | 2026-05-13 | INSM | Insmed Inc | Flammer Martina M.D. | Chief Medical Officer | S - Sale | $116.12 | -18,333 | 64,910 | -22% | -$2,128,892 | |||||
2026-05-14 | KPTI | Karyopharm Therapeutics Inc. | Rangwala Reshma | EVP, Chief Medical Officer | S - Sale | $9.50 | -408 | 56,829 | -1% | -$3,876 | ||||||
2026-05-13 | INSM | Insmed Inc | Smith Michael Alexander | GC | S - Sale | $116.18 | -4,109 | 47,762 | -8% | -$477,384 | ||||||
2026-05-13 | INSM | Insmed Inc | Lewis William | Chair, CEO | S - Sale | $116.18 | -13,283 | 521,826 | -2% | -$1,543,219 | ||||||
2026-05-14 | KPTI | Karyopharm Therapeutics Inc. | Cheng Sohanya Roshan | EVP, Chief Commercial Officer | S - Sale | $9.50 | -324 | 107,940 | 0% | -$3,078 | ||||||
2026-05-13 | COLL | Collegium Pharmaceutical, Inc | Lurker Nancy | Dir | S - Sale | $35.97 | -4,500 | 18,017 | -20% | -$161,861 | ||||||
2026-05-14 | KPTI | Karyopharm Therapeutics Inc. | Abate Kristin | Chief Accounting Officer | S - Sale | $9.50 | -53 | 23,801 | 0% | -$504 | ||||||
2026-05-14 | KPTI | Karyopharm Therapeutics Inc. | Paulson Richard A. | Pres, CEO | S - Sale | $9.50 | -2,203 | 269,747 | -1% | -$20,929 | ||||||
2026-05-14 | KPTI | Karyopharm Therapeutics Inc. | Mano Michael | EVP, CLO, Secretary | S - Sale | $9.50 | -266 | 94,398 | 0% | -$2,527 | ||||||
2026-05-14 | HROW | Harrow, Inc. | Baum Mark L | CEO | P - Purchase | $30.20 | +10,000 | 2,996,130 | 0% | +$302,000 | ||||||
2026-05-14 | HROW | Harrow, Inc. | Boll Andrew R. | Pres, CFO | P - Purchase | $29.90 | +3,500 | 814,679 | 0% | +$104,650 | ||||||
| DM | 2026-05-01 | LGND | Ligand Pharmaceuticals Inc | Kozarich John W | Dir | S - Sale+OE | $225.14 | -2,501 | 41,786 | -6% | -$563,080 | |||||
| AD | 2026-05-12 | PTGX | Protagonist Therapeutics, Inc | Patel Dinesh V Ph D | Pres, CEO | S - Sale+OE | $100.12 | -75,000 | 523,478 | -13% | -$7,509,000 | |||||
| D | 2026-05-12 | STTK | Shattuck Labs, Inc. | Shukla Abhinav A. | Chief Technical Officer | S - Sale+OE | $7.01 | -2,032 | 81,258 | -2% | -$14,244 | |||||
2026-05-12 | STTK | Shattuck Labs, Inc. | Pandite Arundathy N. | Chief Medical Officer | S - Sale | $6.61 | -30,000 | 166,219 | -15% | -$198,300 | ||||||
2026-05-12 | ARWR | Arrowhead Pharmaceuticals, Inc. | Lu Hongbo | Dir | S - Sale | $76.88 | -2,970 | 52,012 | -5% | -$228,334 | ||||||
| D | 2026-05-13 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $578.65 | -9,500 | 679,797 | -1% | -$5,497,166 | |||||
2026-05-14 | CYTK | Cytokinetics Inc | Blum Robert I | Pres, CEO | S - Sale | $77.92 | -7,500 | 404,496 | -2% | -$584,400 | ||||||
2026-05-13 | RCKT | Rocket Pharmaceuticals, Inc. | Wilson Martin | GC | S - Sale | $3.61 | -3,361 | 678,639 | 0% | -$12,120 | ||||||
2026-05-13 | RCKT | Rocket Pharmaceuticals, Inc. | Shah Gaurav | CEO | S - Sale | $3.61 | -2,728 | 1,449,565 | 0% | -$9,837 | ||||||
2026-05-13 | RCKT | Rocket Pharmaceuticals, Inc. | Militello John | See Remarks | S - Sale | $3.61 | -855 | 90,164 | -1% | -$3,083 | ||||||
| M | 2026-05-12 | ZOMDF | Zomedica Corp. | Powers Johnny D | Dir | P - Purchase | $0.11 | +300,000 | 4,225,000 | +8% | +$31,700 | |||||
| D | 2026-05-12 | LTRN | Lantern Pharma Inc. | Schalop Lee Troy | Dir | P - Purchase | $2.06 | +48,544 | 48,544 | New | +$100,001 | |||||
| D | 2026-05-12 | LTRN | Lantern Pharma Inc. | Keyser D Jeffrey | Dir | P - Purchase | $2.06 | +48,544 | 94,303 | +106% | +$100,001 | |||||
2026-05-12 | VRTX | Vertex Pharmaceuticals Inc / Ma | Bozic Carmen | EVP, CMO | S - Sale | $450.00 | -6,988 | 26,088 | -21% | -$3,144,600 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |